Cargando…
Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer
Prostate cancer is the second most frequent malignancy in men worldwide and the fifth leading cause of death by cancer. Although most patients initially benefit from therapy, many of them will progress to metastatic castration-resistant prostate cancer, which still remains incurable. The significant...
Autores principales: | Lankoff, Anna, Czerwińska, Malwina, Kruszewski, Marcin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223532/ https://www.ncbi.nlm.nih.gov/pubmed/37241862 http://dx.doi.org/10.3390/molecules28104122 |
Ejemplares similares
-
Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives
por: Czerwińska, Malwina, et al.
Publicado: (2020) -
Design and Evaluation of (223)Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy–Part I
por: Czerwińska, Malwina, et al.
Publicado: (2020) -
Design and Evaluation of (223)Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution
por: Lankoff, Anna, et al.
Publicado: (2021) -
Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates
por: Staudacher, Alexander H, et al.
Publicado: (2018) -
A Bombesin-Shepherdin Radioconjugate Designed for Combined Extra- and Intracellular Targeting
por: Fischer, Christiane A., et al.
Publicado: (2014)